FYE | FYE | FYE | FYE | FYE | FYE | FYE | FYE | FYE | FYE | |||||
Dec | Dec | Dec | Dec | Dec | Dec | Dec | Dec | Dec | Dec | |||||
Regeneron Pharmaceuticals | 2018 | 2017 | 2017 | 2016 | 2016 | 2015 | 2015 | 2014 | 2014 | 2013 | ||||
Top-Tier | Total | Total | Total | Total | Total | Total | Total | Total | Total | Total | ||||
Executive | Comp | Comp | Comp | Comp | Comp | Comp | Comp | Comp | Comp | Comp | ||||
$ 000s | $ 000s | $ 000s | $ 000s | $ 000s | $ 000s | $ 000s | $ 000s | $ 000s | $ 000s | |||||
Schleifer CEO | 26,521 | 26,508 | 26,508 | 28,338 | 28,338 | 47,463 | 47,463 | 41,965 | 41,965 | 36,273 | ||||
Yancopoulos Chief Scientific Officer | 25,381 | 25,299 | 25,299 | 27,768 | 27,768 | 40,302 | 40,302 | 35,507 | 35,507 | 31,018 | ||||
Landry CFO | 9,357 | 4,795 | 4,795 | 5,165 | 5,165 | 8,249 | 8,249 | 7,373 | N/A | N/A | ||||
Van Plew | 9,007 | 8,979 | ||||||||||||
Stahl EVP R&D | 9,137 | 10,985 | 10,985 | 18,375 | 18,375 | 16,254 | 16,254 | 14,355 | ||||||
Terifay | 6,771 | 11,157 | 11,157 | 8,396 | 8,396 | 7,679 | ||||||||
70,266 | 65,581 | 65,739 | 72,256 | 79,027 | 125,546 | 125,546 | 109,495 | 102,122 | 89,325 | |||||
Annual % Change vs Prior Year | 7.1% | -9.0% | -37.1% | 14.7% | 14.3% | |||||||||
5 Year Average Per Year % Change | -2.0% | |||||||||||||
FYE | FYE | FYE | FYE | FYE | FYE | FYE | FYE | FYE | FYE | |||||
Dec | Dec | Dec | Dec | Dec | Dec | Dec | Dec | Dec | Dec | |||||
Regeneron Pharmaceuticals | 2013 | 2012 | 2012 | 2011 | 2011 | 2010 | 2010 | 2009 | 2009 | 2008 | ||||
Top-Tier | Total | Total | Total | Total | Total | Total | Total | Total | Total | Total | ||||
Executive | Comp | Comp | Comp | Comp | Comp | Comp | Comp | Comp | Comp | Comp | ||||
$ 000s | $ 000s | $ 000s | $ 000s | $ 000s | $ 000s | $ 000s | $ 000s | $ 000s | $ 000s | |||||
Schleifer CEO | 36,273 | 30,047 | 30,047 | 10,563 | 10,563 | 7,588 | 7,588 | 6,349 | 6,349 | 2,554 | ||||
Yancopoulos Chief Scientific Officer | 31,018 | 81,551 | 81,551 | 10,027 | 10,027 | 13,352 | 13,352 | 5,108 | 5,108 | 1,944 | ||||
Landry CFO | N/A | N/A | ||||||||||||
Van Plew | ||||||||||||||
Stahl EVP R&D | 14,355 | 11,995 | 11,995 | 3,150 | 3,150 | 4,520 | 4,520 | 2,867 | 2,867 | 1,102 | ||||
Terifay | 7,679 | 7,478 | ||||||||||||
Goldberg | 2,711 | 9,623 | 9,623 | 3,106 | 3,106 | 3,638 | 3,638 | 2,015 | 2,015 | 993 | ||||
Totals | 92,036 | 140,694 | 133,216 | 26,846 | 26,846 | 29,098 | 29,098 | 16,339 | 16,339 | 6,593 | ||||
Annual % Change vs Prior Year | -34.6% | 396.2% | -7.7% | 78.1% | 147.8% | |||||||||
5 Year Average Per Year % Change | 116.0% | |||||||||||||
5 Year Average Per Year % Change | 57.0% |
Tuesday, March 24, 2020
Tarrytown, New York-Based Regeneron Pharmaceuticals' Top-Tier Executives Average Annual Pay and Benefits Increase During the Past Ten Years Was a Blistering 57.0% Per Year
From Company Proxy Statement filings with the SEC, below are Regeneron Pharmaceuticals Inc's Top-Tier Executives Annual Total Compensation for each of two consecutive full years of employment for the most recent ten years.